Journal of Clinical Virology - Volume 82 - Supplement 1 - September 2016

74 / 152

S70 Abstracts / Journal of Clinical Virology 82S (2016) S1–S142
apy must be considered according to HBV DNA and HBV risk with
closely monitoring.
Abstract no: 191
Presentation at ESCV 2016: Poster 98
The distribution of hepatitis C virus genotypes
of patients with chronic hepatitis C infection in
Eskisehir Region of Turkey
T. Us ∗, N. Kasifoglu , F.G. Aslan , M. Aslan ,
Y. Akgun Durmaz
1 Eskisehir Osmangazi University, Faculty of
Medicine, Department of Microbiology, Eskisehir,
Turkey
2 Sakarya University, Faculty of Medicine,
Department of Microbiology, Sakarya, Turkey
Chronic hepatitis C is a serious disease than can result in long-
term health problems. At least 6 major HCV genotypes and more
than 100 subtypes were determined. It is known that different
genotypes in HCV infections account for differences in disease
courses and treatment responses. In our study, it is aimed to deter-
mine HCV genotype distribution to suggest treatment responses of
patients with chronic hepatitis C infection.
In this study, anti-HCV, HCV RNA viral loads and HCV genotypes
of 203 patients followed-up in Eskisehir Osmangazi University
Medical Faculty between 2009 and 2014 were investigated. Anti-
HCV was tested by microparticle ELISA (Abbott AxSYM System
HCV 3.0). HCV-RNA viral loads were determined by Artus HCV RG
PCR kit (Qiagen, Germany) on Rotor-Gene 6000 (Corbett Research)
instrument after extraction by Biorobot M48 system (Qiagen,
Germany) between 2009 and 2011, and by Cobas TaqMan 48
(Roche, Germany) system after extraction by Cobas AmpliPrep
(Roche) between 2011 and 2014 by Real Time PCR. HCV genotyp-
ing of HCV RNA positive patients was performed by HCV genotype
Pyrosequencing test (Qiagen, Germany).
Eighty-seven (42.86%) of 203 patients were male and 116
(57.14%) were female. The average age of the patients was as 54.97
and the age range was 14–77. The distribution of HCV genotypes
was as following: in 151 (74.4%) patients genotype 1; in 3 (1.4%)
genotype 2; in 4 (1.9%) genotype 3; in 4 (1.9%) genotype 4. In 151
patients who were positive for genotype 1, genotype 1b was pos-
itive in 36 (17.7%) and 3–8.35 × 107. In 191 (94.0%) patients anti
HCV was positive and in 12 (6.0%) anti HCV was negative.
The most common HCV genotype in chronic hepatitis C patients
followed up in Eskisehir region was genotype 1, and the most com-
mon subtype in this group was genotype 1b. Treatment protocols
should be reevaluated by taking into consideration that sustained
viral response in these patients might be weak. In Turkey, approxi-
mately 90% of HCV infections are by type 1 (most are type 1b), and
type 2, 3, and 4 HCV infections are seen.
Abstract no: 194
Presentation at ESCV 2016: Poster 99
Change in the prevalence of hepatitis E virus in
the last 15 years, Turkey
S.B. Aykan ∗, F.G. Aslan , M. Altindis
1 Sakarya University Vocational School of Health
Services, Department of Medical Laboratory
Techniques, Sakarya, Turkey
2 Sakarya University Faculty of Medicine,
Department of Medical Microbiology, Sakarya,
Turkey
Objective: Hepatitis A, B and E infections are community health
problems in developing countries and the most common acute
viral hepatitis in children. Hepatitis E virus (HEV) causes epidemics
in developing countries. Turkey represents a bridge between HEV
endemic and non-endemic areas, and HEV may cause epidemics
in Turkey. The epidemiology of HEV infections are best defined by
measuring humoral antibodies in children. For this reason the pur-
pose of this study was to detect the change in the prevalence of
HEVantibody by systematic reviews inpublishedmedical literature
from 2000 to 2015 years in Turkey.
Materials and methods: The study was planned and conducted
in accordancewith the declaration of PRISMA. To find the published
series, two national databases (ULAKBIM and TURK MEDLINE) and
one international database (PubMed) were investigated. Published
manuscripts were evaluated according to the determined criteria
for acceptance and rejection. For each study, anti-HEV IgG and anti-
HEV IgM antibody rates were collected as a common unit.
Results: After screening according to the applied acceptance and
rejection criteria, 13 studies published between 2000 and 2015
were included in the study for evaluating HEV antibodies sero-
prevalence. Anti-HEV IgM 4.15 ± 4.73 and anti-HEV IgG 4.24 ±4.67
(mean ±SD) between 2000 and 2015. Anti-HEV IgG seroprevalence
under the five years 2.56 ±2.63, five to nine years 2.00 ± 2.47, 10–16
years 2.03 ±2.73, respectively. It has been defined that the ratio of
anti-HEV IgG changed between 0% and 17.3% in different studies
done between the years 2000 and 2015 in our country.
Conclusion: In conclusion, we evaluated more than 5000 Turk-
ish children HEV antibody prevalence more than 15 years period.
Frequency of HEV infection varies greatly depending on geographic
region, socioeconomic level, age and various risk factors. To take
preventive measures to protect themselves from infection with
HEV is important to know the prevalence of HEV.